~~<i id='498B481073'><strike id='498B481073'><tt id='498B481073'><pre id='498B481073'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：knowledge 2025-09-03 09:23:19 - browse：39

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： AstraZeneca lung cancer study comes in below expectations

focus

Wikipedia

leisure time

explore

leisure time

focus

2:22NASA'sJamesWebbSpaceTelescoperevealsStephan'sQuintetinanewlight.Avisualgroupingoffivegalaxies,is

WSS

HHS's proposed rule does nothing to address the climate crisis

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Chemotherapy before breast cancer surgery might fuel metastasis

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Chemotherapy before breast cancer surgery might fuel metastasis

The wait for US passports is creating travel purgatory and snarling summer plans

hotspot

explore

focus

Medicare proposal to cover medical devices draws a mixed reaction

PBM executives asked to testify by House panel

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Class action alleges UnitedHealth concealed DOJ probe

Duchenne breakthrough therapy leaves behind pioneering families

GSK’s asthma push continues as drug succeeds in Phase 3 trials

DIEP, the 'gold standard' of breast reconstruction, is under threat

As billionaires fund anti

Supreme Court strikes down use of affirmative action

AstraZeneca lung cancer study comes in below expectations

Wikipedia

Brain technologies pose threats that are all too real, experts warn

AltruBio raises $225 million to develop ulcerative colitis drug

AltruBio raises $225 million to develop ulcerative colitis drug

Novel spinal cord stimulator treats paralysis without surgery

Beware reading your test results before your doctor does

Deliver public health messages at the right time

leisure time

explore

leisure time

focus